Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients

Archives of Medical Research

Volumn 36, Issue 1, 2005, Pages 49-53

  Aarons, Leon ^a   Ahmed, Ikhlas Ali ^b   Deleu, Dirk ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Dept Clin Pharmacol Therapeut ^*  (Oman)

^c HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

Epilepsy; Michaelis Menten kinetics; NONMEM; Oman; Phenytoin; Population pharmacokinetics; Protein binding

Indexed keywords

PHENYTOIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; EPILEPSY; EVALUATION; FEMALE; HUMAN; INDIVIDUALITY; INFORMATION PROCESSING; MALE; MEDICAL INFORMATION; METABOLIC RATE; MICHAELIS CONSTANT; MONOTHERAPY; NONLINEAR SYSTEM; PARAMETER; PROTEIN BINDING; SAMPLE SIZE; SIDE EFFECT; STATISTICAL MODEL;

EID: 15244356908     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2004.11.006     Document Type: Article

References (37)

1. B. Andoh, J.R. Idle, T.P. Sloan, R.L. Smith, and N. Woolhouse Inter-ethnic and inter-phenotype differences among Ghanaians and Caucasians in the metabolic hydroxylation of phenytoin Br J Clin Pharmacol 9 1980 282P 283P
2. S.M. Bryson, Y. Al-Lanqawi, A.W. Kelman, and B. Whiting Comparison of a Bayesian forecasting technique with a new method for estimating phenytoin dose requirements Ther Drug Monit 10 1988 80 84
3. M. Levine, and T. Chang Therapeutic drug monitoring of phenytoin: rationale and current status Clin Pharmacokinet 19 1990 341 358
4. G.M. Peterson, S. MacLean, S. Aldous, R.J. Von Witt, and K.S. Millingen Plasma protein binding of phenytoin in 100 epileptic patients Br J Clin Pharmacol 14 1982 298 300
5. S. Vozeh, K.T. Muir, L.B. Sheiner, and F. Follath Predicting individual phenytoin dosage J Pharmacokinet Biopharm 9 1981 131 146
6. L.B. Sheiner, and S.L. Beal Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data J Pharmacokinet Biopharm 8 1980 553 571
7. M.E. Burton, M.R. Vasko, and D.C. Brater Comparison of drug dosing methods Clin Pharmacokinet 10 1985 1 37
8. G.J. Yuen, J.W. Taylor, T.M. Ludden, and M.J. Murphy Predicting phenytoin dosages using Bayesian feedback: a comparison with other methods Ther Drug Monit 5 1983 437 441
9. T.H. Grasela, L.B. Sheiner, B. Rambeck, H.E. Boenigk, A. Dunlop, P.W. Mullen, J. Wadsworth, A. Richens, T. Ishizaki, and K. Chiba Steady-state pharmacokinetics of phenytoin from routinely collected patient data Clin Pharmacokinet 8 1983 355 364
10. E. Chan, T.Y. Ti, and H.S. Lee Population pharmacokinetics of phenytoin in Singapore Chinese Eur J Clin Pharmacol 39 1990 177 181
11. R. Miller, M. Rheeders, C. Klein, and I. Suchet Population pharmacokinetics of phenytoin in South African black patients S Afr Med J 72 1987 188 190
12. P. Valodia, M.A. Seymour, R. Miller, M.L. McFadyen, and P.I. Folb Factors influencing the population pharmacokinetic parameters of phenytoin in adult epileptic patients in South Africa Ther Drug Monit 21 1999 57 62
13. E. Yukawa, S. Higuchi, and T. Aoyama Population pharmacokinetics of phenytoin from routine clinical data in Japan: an update Chem Pharm Bull (Tokyo) 38 1990 1973 1976
14. Commission on Epidemiology and prognosis, International League Against Epilepsy Guideliness for epidemiologic studies on epilepsy Epilepsia 34 1993 592 596
15. Commission on Classification and Terminology of the International League Against Epilepsy Proposal for revised clinical and electroencephalographic classification of epileptic seizures Epilepsia 22 1981 489 501
16. G.L. Birbeck, R.D. Hays, X. Cui, and B.G. Vickrey Seizure reduction and quality of life improvements in people with epilepsy Epilepsia 43 2002 535 538
17. D. Deleu, L. Aarons, and I. Ahmed Population pharmacokinetics of free-carbamazepine in adult Omani epileptic patients Eur J Clin Pharmacol 57 2001 243 248
18. E. Yukawa Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring Clin Pharmacokinet 31 1996 120 130
19. J.C. Argyle, D.W. Kinniburgh, R. Costa, and T. Jennison Evaluation of an ultrafiltration-fluorescence polarization immunoassay for monitoring unbound phenytoin Ther Drug Monit 6 1984 117 120
20. K.F. Loomis, and R.M. Frye Evaluation of the Abbott TDx for the stat measurement of phenobarbital, phenytoin, carbamazepine, and theophylline Am J Clin Pathol 80 1983 686 691
21. B.J. Gurley, M. Marx, and K. Olsen Phenytoin free fraction determination: comparison of an improved direct serum injection high-performance liquid chromatographic method to ultrafiltration coupled with fluorescence polarization immunoassay J Chromatogr B Biomed Appl 670 1995 358 364
22. A.J. Boeckmann, L.B. Sheiner, and S.L. Beal NONMEM Users guide 1994 University of California San Fransisco
23. A. Richens, and A. Dunlop Serum-phenytoin levels in management of epilepsy Lancet 2 1975 247 248
24. B. Rambeck, H.E. Boenigk, A. Dunlop, P.W. Mullen, J. Wadsworth, and A. Richens Predicting phenytoin dose - a revised nomogram Ther Drug Monit 1 1979 325 333
25. F.C. Robinson, and P.R. Mayer A graphic method for predicting individual phenytoin levels in an office practice Ther Drug Monit 4 1982 225 228
26. A.J. Armijo, and E. Cavada Graphic estimation of phenytoin dose in adults and children Ther Drug Monit 13 1991 507 510
27. Y. Hanssens, D. Deleu, K. Al Balushi, A. Al Hashar, and I. Al Zakwani Drug utilization pattern of antiepileptic drugs: a pharmacoepidemiologic study in Oman J Clin Pharm Ther 27 2002 357 364
28. G.M. Peterson, B.H. Khoo, and R.J. von Witt Clinical response in epilepsy in relation to total and free serum levels of phenytoin Ther Drug Monit 13 1991 415 419
29. M. Eichelbaum Defective oxidation of drugs: pharmacokinetic and therapeutic implications Clin Pharmacokinet 7 1982 1 22
30. M. Watanabe, K. Iwahashi, T. Kugoh, and H. Suwaki Phenytoin kinetics in Japanese adult epileptics: phenotype of phenytoin slow metabolizers Clin Neuropharmacol 20 1997 346 351
31. A.L. Sherwin, J.S. Loynd, G.W. Bock, and C.D. Sokolowski Effects of age, sex, obesity, and pregnancy on plasma diphenylhydantoin levels Epilepsia 15 1974 507 521
32. A. Richens Clinical pharmacokinetics of phenytoin Clin Pharmacokinet 4 1979 153 169
33. R. Ismail, A.F. Rahman, and P. Chand Pharmacokinetics of phenytoin in routine clinic patients in Malaysia J Clin Pharm Ther 19 1994 245 248
34. L.A. Bauer, and R.A. Blouin Age and phenytoin kinetics in adult epileptics Clin Pharmacol Ther 31 1982 301 304
35. M. Abduljabbar, K. Al-Khamis, A. Ogunniyi, A.K. Daif, and M. Al-Yamani Phenytoin dosage adjustment in Saudi epileptics: utilization of steady-state pharmacokinetic parameters Eur J Neurol 6 1999 331 334
36. T.D. Bjornsson, J.A. Wagner, S.R. Donahue, D. Harper, A. Karim, M.S. Khouri, W.R. Murphy, K. Roman, D. Schneck, D.S. Sonnichsen, D.J. Stalker, S.D. Wise, S. Dombey, and C. Loew A review and assessment of potential sources of ethnic differences in drug responsiveness J Clin Pharmacol 43 2003 943 967
37. J.Z. Rui, M.H. Cai, X.M. Chu, and G. Chen NONMEM approach for estimating population pharmacokinetic parameters of phenytoin in Chinese epileptics Yao Xue Xue Bao 30 1995 172 178